Full-Time

Direct to Patient Team Lead

Posted on 8/15/2025

Blueprint Medicines

Blueprint Medicines

501-1,000 employees

Biopharma developing kinase inhibitors for cancer

Compensation Overview

$220k - $275k/yr

+ Annual Bonus

Cambridge, MA, USA

Hybrid

Category
Growth & Marketing (1)
Requirements
  • BA/BS degree required; advanced degree, MBA, or other equivalent experience preferred
  • Minimum of 8+ years of experience in strategic roles within the biotech/pharmaceutical industry, including direct involvement in marketing, sales, or market development activities
Responsibilities
  • Lead the US AYVAKIT patient marketing team, develop an industry-leading Direct-to-Patient team who are enthusiastic about patient marketing. Your strategic guidance and mentorship will empower them to deliver impactful campaigns and initiatives
  • Provide leadership to Blueprint Medicines and brand team to enable development, alignment and execution of patient strategy across the organization
  • Spearhead cross-functional collaboration and alignment to ensure patient strategies are integrated across Blueprint Medicines, including leading broader patient connect team across organization
  • Collect actionable patient insights that help understand the SM landscape, identify the emergent needs of SM patients and caregivers, guiding and encouraging understanding of insights cross functionally
  • Guide the development and execution of core patient-facing initiatives, including the disease awareness campaign, AYVAKIT campaign updates, digital/print media, conferences, and non-personal tactics
  • Provide strategic oversight for the Patient Ambassador Program (unbranded and branded), including programming strategy, goals and KPIs
  • Lead digital marketing capability evolution (in collaboration with commercial operations) to ensure team can execute on multichannel promotion campaigns
  • Accountable to patient-focused brand plan, proposing programs and capabilities needed to support the strategy and championing that plan through engagement with cross-functional partners
  • Collaborate with legal, regulatory, and compliance stakeholders to ensure compliant development and execution of educational programming
  • Required travel: Up to 25%
  • Perform other responsibilities as assigned.
Desired Qualifications
  • Previous in-line marketing experience a must, with core focus on patient strategy, franchise management, and cross-functional leadership
  • Deep experience in developing patient engagement strategies & tactics for pharmaceutical or biotech products in the US
  • Demonstrated ability to work effectively on cross-functional matrix teams, leading without authority
  • Expertise with omnichannel, media planning, and integrated promotion with an emphasis on digital and social media strategy
  • Experience working on launch products where DTP is central to brand success needed
  • Experience in rare disease, oncology and/or new markets preferred
  • Demonstrated track record of complex project management and effective vendor management
  • Excellent written and communication skills
  • Proven ability to influence without authority and work with cross-functional teams in the development and delivery of brand strategic imperatives
  • A team player who can take an enterprise view, influence without authority, gain consensus rapidly and act independently in a fast-paced environment
  • Broad degree of professional versatility with internal drive and curiosity to take on new and challenging roles and responsibilities
  • Flexibility and the ability to plan and nimbly adapt strategy and approaches to changing conditions
  • Motivated by patient focus, urgency and personal commitment to high performance, results and compliance. Possesses high integrity and exceptional work ethic
  • Commitment to our Core Values: Patients First, Thoughtfulness, Urgency, Trust, Optimism

Blueprint Medicines develops and commercializes kinase inhibitors for cancer and other diseases. Its lead product, Ayvakit (avapritinib), blocks enzymes that drive tumor growth in gastrointestinal stromal tumors with PDGFRA exon 18 mutations. The company also has a pipeline of other kinase inhibitors in clinical development for lung, breast, and blood cancers, plus preclinical programs in immunology and rare diseases. By performing discovery, development, and commercialization in-house, it aims to bring targeted therapies to patients with unmet medical needs and expand its global oncology portfolio.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi $9.1B acquisition on June 2, 2025, boosts immunology portfolio and resources.
  • AI and machine learning enhance drug discovery productivity since recent integration.
  • Targeted protein degradation expansion via 2022 VantAI collaboration diversifies pipeline.

What critics are saying

  • Sanofi integration disrupts sales force, eroding Ayvakit market share in 12-18 months.
  • FDA black box warnings for Ayvakit hemorrhage drop prescriptions 20-30% in 6-12 months.
  • Generic avapritinib from Dr. Reddy's captures 40% GIST market by 2028.

What makes Blueprint Medicines unique

  • Ayvakit is the only FDA-approved treatment targeting PDGFRA D842V mutations in GIST.
  • PIONEER four-year data confirm AYVAKIT's sustained efficacy in indolent systemic mastocytosis.
  • BLU-808 shows wide therapeutic window as first-in-class oral wild-type KIT inhibitor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Mental Health Support

Employee Stock Purchase Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

5%

2 year growth

3%
Fusacq
Jun 2nd, 2025
Sanofi Acquires Blueprint Medicines Biotech

Sanofi has acquired the American biotech company Blueprint Medicines, which specializes in systemic mastocytosis, a rare disease characterized by abnormal activation or proliferation of mast cells in tissues, most commonly the skin and bone marrow.

Google
Jun 2nd, 2025
Sanofi Acquires Blueprint for $9.1B

Sanofi is set to acquire Blueprint Medicines for an equity value of $9.1 billion, according to Bloomberg.

Investors Hangout
Jun 2nd, 2025
Sanofi Acquires Blueprint for $9.1B

Sanofi is acquiring Blueprint Medicines for approximately $9.1 billion, enhancing its immunology portfolio. This acquisition includes Ayvakit, the only FDA-approved treatment for systemic mastocytosis, and promising therapies like elenestinib and BLU-808. Sanofi will finance the deal with cash and new debt, expecting it to boost gross margin and operating income post-2026. The merger aligns with Sanofi's strategy to lead in immunology and address rare diseases.

The Gazette
Jun 2nd, 2025
Sanofi to buy US biopharma group Blueprint for up to $9.5 billion

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year, according to LSEG data.

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

INACTIVE